Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ANP website updated.
https://www.anptinc.com/
Is it time for PR storm now ?
Added some @ $14.04 thought it was bottom ohh well.
Took my loss in $PULM and added more $PDSB I´m sure its a much better decision.
I think we hear news about ANP deal very very soon.
Could hear news monday AH IMO...
Thanks for all the good DD Fress..
Feel free to post your DD on the Community, since I am trying to bring more focus on $PDSB
https://www.reddit.com/r/PDSB_Biotech/
Thank you 1776club I love reading your post here.
So positive and I will also keep my shares in $SRNE first target is around $50 might sell 30% there and keep rest and wait for triple $ PPS...
$IDEX ADDED more shares today @ $2.67
Wish I had free funds to add, but I am fully loaded :(
Go $PDSB
Baba biggest fear was breaking it down and what not. Money fine is the best outcome baba could ever have. 2.8 billion in grand scheme of things is negligible. Baba should gap up Monday. Possible 240 break this week. 260 on higher end. More clarity after the conference call today at 8 est. ignore the noise.
$PDSB stay strong and hold $$$ incoming...
New Release
Zhitong Finance APP learned that Dawson James analyst Jason Kolbert issued a research report and gave Sorrento (SRNE.US) a "buy" rating with a target price of $19. This figure means that the stock will rise strongly by 177% in 12 months. .
It is reported that earlier this week, Sorrento announced that it would acquire ACEA Therapeutics, an advanced cancer treatment company, for US$38 million. ACEA equity holders will also receive a milestone payment of up to US$450 million and 5-10% of annual net sales. Royalties.
The acquisition will include the clinical late-stage drug Abivertinib, the clinical-stage drug candidate AC0058, the pre-clinical-stage drug candidate AC0939, and ACEA's extensive library of small molecule proprietary compounds (more than 1,000,000 compounds), which may be suitable for a variety of human disease adaptations Symptoms, including non-small cell lung cancer (NSCLC), B-cell lymphoma, systemic lupus, rheumatoid arthritis, multiple sclerosis and viral infections.
The analyst believes that the "core" of the transaction is Abivertinib. In addition to non-small cell lung cancer, Abivertinib may also improve the efficacy of drug-resistant prostate cancer, systemic lupus erythematosus and various B-cell lymphomas. Currently, ACEA is carrying out a Phase II clinical study of Abivertinib for the treatment of respiratory damage caused by COVID-19 in the United States and Brazil.
The analyst also pointed out that through this acquisition, Sorrento will also obtain ACEA's most advanced cGMP facility in Quzhou, China, which is located in a 23-acre park with five buildings.
Kolbert believes that ACEA is similar in many respects to BeiGene (BGNE.US), which has a market value of approximately US$32 billion.
$PDSB might see some analytics upgrade PT very soon. $25-$30 is first upgrade IMO
$PDSB
DD on reddit Community.
Everyone is welcome and good shared DD is wanted , especially you Fress:)
Link:
https://reddit.com/r/PDSB_Biotech/
Think we going up today !!!!
Finally some positive volume.
Time to go back up :).
Thanks I will share this on Reddit.
Thanks for nice DD. Diamond hands!!!
Cover cover shorts hurry up or you will be burned.
Volume coming in and we going back up fast.
Lovely list with programs.. Thanks dia76ca :)
hopefully we get it soon!!!
Depends what we get next. FDA approval for Covi-stix ?
HudHud (poster on Stocktwits) Shared a very interesting speculation:
Pulmatrix might be partnering with Allergan (ABBVIE) ?
https://www.oindpnews.com/2021/03/pulmatrix-announces-development-plans-for-pur3100-inhaled-dry-powder-dhe-for-the-treatment-of-migraine/
to solve crl ?
https://www.oindpnews.com/2014/06/allergan-gets-another-crl-for-semprana-formerly-levadex-inhaled-dhe/
Might be coming a big partnership here IMO
From zzyxz:
$PULM
Time is in our favor. I believe April is when we enter the hot zone of "milestones rich 2021."
Below is from the 8-K filing:
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14818441&RcvdDate=3/23/2021&CoName=PULMATRIX,%20INC.&FormType=8-K&View=html
"We look forward to a milestone rich 2021 which includes toxicology and clinical data packages from ongoing PUR1800 studies, potential license option execution from Johnson & Johnson, and continued execution as we advance therapies to address significant unmet need."
======
Let's break it down:
1) toxicology and clinical data packages (PUR1800)
2) potential license option execution (J&J)
3) advance therapies to address significant unmet need
I gather that each one of the above has the potential to raise the PULM price ceiling. Positive news on #1 will go a long way to support a higher price level. #2 may open the flood gate by new investors depending on the type of license option executed by J&J. #3 New therapies not mentioned before will expand Pulmatrix's pipelines and make it more attractive for acquisition.
Try again
$PULM
Events section seems to be updated after very long time.
KOL Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine Date: April 23rd.
https://filecache.investorroom.com/mr5ir_pulmatrix/214/download/Pulmatrix%20KOL%20Webinar%204.23.21_Invite.pdf
Hope next week will be bouncing :)
Thank you @NGVGlobalGroup and #GreenPathLogistics for joining us on the journey towards reduced emissions and congratulations on your Hybrid Electric CNG installs. pic.twitter.com/knsT9KhzcK
— Hyliion (@Hyliion) April 2, 2021
This guy bought
$AMD under $5
$SPCE at $15.
$FCEL under $5
His #1 pick is Fisker for 2021.
Now at $17 he sees $400 by 2025
This guy shows his portfolio buying $4,000,000 in
$FSR
Stock, he sees it going from $17 to $400 a share.
$HYLN
Finally a partnership, contract & sales!!!!! ??????
$0.28 is where the big money is buying, so I´m added more shares today @ 0.28..
Brand Capital International has agreed to purchase 9,025,000 common shares in the capital of QYOU Media at a price of C $0.28 per share for an aggregate investment of US $2 million (C $2,527,000).
I´m all in today.. $QYOU will be running to .50 cents very soon.
Sorrento has over 50 drug programs!
Phase 3 or close to EUA (11 programs)
1. Abivirtinib NSCLC
2. PD-L1 partnered
3. Erbitux biosimilar
4. Xolair biosimilar
5. Remicade biosimilar
6. SP-102 sciatica
7. RTX Osteo Arthritis
8. RTX cancer pain
9. Covi-Stix EUA application
10. Covi-Trace EUA application
11. Cynviloq (part of PSS lawsuit)
Phase 2 (11 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential
4. Covi-Track EUA pre-validation
5. PD-L1 partnered
6. Herceptin delivery partnered
7. Abivirtinib Lymphoma
8. Abivirtinib Covid 19
9. Abivirtinib prostate cancer ph.2 IND
10. Abivirtinib Lupus ph.2 IND
11. CD47 partnered
Phase 1, IND filed or pre-IND (28+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T IND
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Covi-Drops ph.1
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1
17. TROP2 pre-IND partnered
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND